Anteris Technologies Ltd
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Anteris Technologies Ltd (AMEUF) is a clinical-stage cardiovascular medtech company focused on developing innovative structural heart therapies using its proprietary Antelin bioadaptive scaffold technology. The company offers a pipeline of products including DurAVF, a bioengineered transcatheter aortic valve replacement (TAVR) system designed for patients with severe aortic stenosis; Adovacy, a next-generation mitral valve replacement system targeting degenerative mitral regurgitation; and early-stage programs for tricuspid regurgitation and coronary artery bypass grafting. These products leverage Antelin's unique anti-calcification properties to enable biological integration and long-term durability without permanent foreign material in the body. Founded in 2012 and headquartered in Melbourne, Australia, Anteris operates globally with research and development facilities in Australia and the United States, targeting patients in the structural heart disease market across North America, Europe, and Asia-Pacific. In recent developments, the company completed enrollment in its global pivotal trial for DurAVF in 2024 and secured FDA Breakthrough Device Designation, advancing toward potential commercialization; it also expanded manufacturing capabilities through a new partnership with a leading contract manufacturer and raised AUD 50 million in a 2024 funding round to support clinical and regulatory milestones.
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris Announces Results for the First Quarter of 2026
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Reports 2025 Financial Results and Provides Corporate Update
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Announces Results for the Third Quarter of 2025
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Announces Results for the Second Quarter of 2025
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering